Home/Filings/4/0000950170-23-071476
4//SEC Filing

Groen Eric 4

Accession 0000950170-23-071476

CIK 0001856725other

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 4:05 PM ET

Size

16.6 KB

Accession

0000950170-23-071476

Insider Transaction Report

Form 4
Period: 2023-12-16
Groen Eric
General Counsel
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-12-16+54,16754,167 total
    Exercise: $2.84Exp: 2031-07-28Class A Common Stock (54,167 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-12-16171,50034,300 total
    Exercise: $5.44Exp: 2033-03-26Class A Common Stock (171,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-12-1643,40031,000 total
    Exercise: $13.21Exp: 2032-03-21Class A Common Stock (43,400 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-12-1654,16775,833 total
    Exercise: $11.00Exp: 2031-07-28Class A Common Stock (54,167 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-12-16+171,500171,500 total
    Exercise: $2.84Exp: 2033-03-26Class A Common Stock (171,500 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-12-16+43,40043,400 total
    Exercise: $2.84Exp: 2032-03-21Class A Common Stock (43,400 underlying)
Footnotes (5)
  • [F1]The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023.
  • [F2]The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date.
  • [F3]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
  • [F4]The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.
  • [F5]The shares subject to the option vest as follows: 25% of the shares subject to the option vest on July 29, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years.

Documents

1 file

Issuer

Rani Therapeutics Holdings, Inc.

CIK 0001856725

Entity typeother

Related Parties

1
  • filerCIK 0001918630

Filing Metadata

Form type
4
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:05 PM ET
Size
16.6 KB